LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $22, Implies 504% Upside
LENZ Therapeutics' average stock price target was reduced from $25 to $22 by analysts, with a range of $7 to $60. This implies a 504% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 7 analysts.
How this was made
The 30-second read
Why it matters
The downward revision of the price target reflects fresh analyst sentiment but retains a Buy rating, indicating mixed views on near‑term performance.
Market read
The target cut is a modest catalyst for LENZ stock, likely causing limited short‑term price movement.
What to watch
Upcoming clinical trial data or partnership announcements could quickly reverse the target cut.
Background
LENZ Therapeutics is a clinical‑stage biotech focused on rare disease treatments. Analyst coverage includes six firms providing price targets.
Market effects
Biotech sector may see slight re‑rating as analysts adjust targets across similar small‑cap therapeutics.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
The large implied upside could signal that the target cut is overly conservative, presenting a buying opportunity.
Key entities
- companyLENZ Therapeutics, Inc.
Biotech firm whose price target was revised.
